Advertisement

Alphabet's Verily offers a more serious take on health monitoring wearables with the Study Watch

Alphabet's Verily offers a more serious take on health monitoring wearables with the Study Watch
From TechCrunch - April 14, 2017

Designed with long-term medical research in mind, the Study Watch has a vastly different set of hardware requirements than your standard smartwatch. The device was designed by Verily, the V in Googles Alphabet, which is devoted to serious medical studies like MS observation and contact lenses capable of monitoring wearers glucose level.

The Study Watch will likewise be tasked with some important research, gathering vital signs for ongoing work like the Personalized Parkinsons Project, which is investigating patterns in the diseases progression and identifyingthe building blocks for a potential cure.

The unassuming wearable will also be used for Baseline, a previously announced study dating back to 2014, which is designed to track the long-term vitals of 175 individuals, in an attempt to build the fullest picture of what a healthy human being should be.

Google was the target of some online criticism when it referred to that project as a moonshot, a term the company has traditionally reserved for wild-eyed projectslike self-driving cars and internet-delivering weather balloons. But while it doesnt possess the glitz of those undertakings, it does point to the broader mission statement of Verily, to collect and organize health data, then creating interventions and platforms that put insights derived from that health data to use for more holistic care management.

The Study Watch, accordingly, doesnt possess the pizzazz of Googles consumer electronics offerings, but from the sound of the companys rundown, its built to be a workhorse. And the fact that it looks and acts like a standard wristwatch goes a ways toward making the data collection process less obtrusive than more traditionalvital-gathering devices. And honestly, its not bad looking.

Advertisement

Continue reading at TechCrunch »